- In a review of clinical characteristics and treatment outcomes in patients with limited-stage mantle cell lymphoma (MCL), patients demonstrated low-risk prognostic scores and clinical characteristics, but eventual relapse was common.
Why this matters
- Although 15% of patients with MCL present with localized (Ann Arbor Stage I or II) disease, little is known regarding optimal clinical features and treatment outcomes.
- Analysis of clinical features and treatment outcomes in 41 patients with limited-stage MCL diagnosed in the years 2000-2016.
- Patient data were sourced from 16 institutions of the Consortium for Improving Survival of Lymphoma group.
- Median patient age at diagnosis: 66 (range, 19-85) years.
- Funding: None disclosed.
- Clinical characteristics:
- 68.3% of patients had low-risk disease per the MCL International Prognostic Index.
- 29.3% of patients were asymptomatic.
- 90.1% of patients received chemotherapy as first treatment.
- Treatment outcomes:
- 97.4% objective response rate.
- 78.0% complete response; 9.8% partial response.
- With 40.6 months median follow-up: 59.1% relapse-free survival (RFS) at 42 months; median OS was not reached.
- 37.6% estimated 5-year RFS; 80.4% estimated 5-year OS.
- Retrospective data.